FDA Warns Against Relying On Screening Tests For Prenatal Diagnosis
The U.S. FDA is warning that noninvasive prenatal screening (NIPS) tests may provide false results, such as stating a…
Goldman Sachs Maintains Neutral on Invitae, Lowers Price Target to $10
Goldman Sachs maintains Invitae (NYSE:NVTA) with a Neutral and lowers the price target from $14 to $10.
Expert Ratings for Invitae
Over the past 3 months, 4 analysts have published their opinion on Invitae (NYSE:NVTA) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.
10 Health Care Stocks Whale Activity In Today’s Session
This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Stocks That Hit 52-Week Lows On Tuesday
During Tuesday's session, 454 stocks hit new 52-week lows.
SVB Leerink Maintains Outperform on Invitae, Lowers Price Target to $25
SVB Leerink analyst Puneet Souda maintains Invitae (NYSE:NVTA) with a Outperform and lowers the price target from $30 to $25.
Stocks That Hit 52-Week Lows On Tuesday
During Tuesday's trading, 505 companies set new 52-week lows.
The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow
Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries.